Search

Your search keyword '"De Boer, R.H."' showing total 15 results
Start Over Author "De Boer, R.H."
15 results on '"De Boer, R.H."'

1. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

Author

Delaloge, S., Cella, D., Ye, Y., Buyse, M., Chan, A., Barrios, C.H., Holmes, F.A., Mansi, J., Iwata, H., Ejlertsen, B., Moy, B., Chia, S.K.L., Gnant, M., Smichkoska, S., Ciceniene, A., Martinez, N., Filipović, S., Ben-Baruch, N.E., Joy, A.A., Langkjer, S.T., Senecal, F., de Boer, R.H., Moran, S., Yao, B., Bryce, R., Auerbach, A., Fallowfield, L., and Martin, M.

Published
2019
Full Text
View/download PDF

2. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

Author

Coleman, R.E., Collinson, M., Gregory, W., Marshall, H., Bell, R., Dodwell, D., Keane, M., Gil, M., Barrett-Lee, P., Ritchie, D., Bowman, A., Liversedge, V., De Boer, R.H., Passos-Coelho, J.L., O'Reilly, S., Bertelli, G., Joffe, J., Brown, J.E., Wilson, C., Tercero, J.C., Jean-Mairet, J., Gomis, R., and Cameron, D.

Published
2018
Full Text
View/download PDF

3. 205P Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials

Author

Yardley, D.A., primary, Yap, Y.S., additional, Azim, H.A., additional, De Boer, R.H., additional, Campone, M., additional, Ring, A., additional, De Laurentiis, M., additional, O'Shaughnessy, J., additional, Cortés, J., additional, Chattar, Y., additional, Thuerigen, A., additional, Zarate, J.P., additional, and Nusch, A., additional

Published
2022
Full Text
View/download PDF

9. Risk Factors for Hypocalcemia in Patients with Cancer Receiving Denosumab

Author

Body, J., primary, Bone, H.G., additional, van Poznak, C., additional, De Boer, R.H., additional, Stopeck, A., additional, Damião, R., additional, Fizazi, K., additional, Henry, D.H., additional, Ibrahim, T., additional, Lipton, A., additional, Saad, F., additional, Shore, N.D., additional, Takano, T., additional, Wang, H., additional, Bracco, O.L., additional, Balakumaran, A., additional, and Kostenuik, P.J., additional

Published
2014
Full Text
View/download PDF

10. AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab

Author

Stopeck, A.T., primary, Lipton, A., additional, Martín, M., additional, Body, J-J., additional, Paterson, A., additional, Steger, G.G., additional, Tonkin, K., additional, de Boer, R.H., additional, Fujiwara, Y., additional, Yardley, D., additional, Jassem, J., additional, Takano, T., additional, Solal-Céligny, P., additional, Fan, M., additional, and Braun, A., additional

Published
2012
Full Text
View/download PDF

11. 412 BMS-754807, an oral dual IGF-1R/insulin receptor (IR) inhibitor: initial results from a Phase 1 dose- and schedule-finding study in combination with carboplatin/paclitaxel in subjects with solid tumors

Author

Chu, Q.S., primary, Kim, S.W., additional, Ellis, P.M., additional, Mileshkin, L., additional, de Boer, R.H., additional, Park, J.S., additional, Pellas, T., additional, Huang, F., additional, Finckenstein, F. Graf, additional, and Dhar, A., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results